The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC.

Aurinia Pharmaceuticals Inc. has announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a ...